756,600 Shares in Grace Therapeutics, Inc. $GRCE Bought by Eversept Partners LP

Eversept Partners LP purchased a new stake in Grace Therapeutics, Inc. (NASDAQ:GRCE) in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 756,600 shares of the company’s stock, valued at approximately $3,503,000. Eversept Partners LP owned approximately 4.89% of Grace Therapeutics as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Stratos Wealth Partners LTD. acquired a new stake in Grace Therapeutics during the fourth quarter worth about $39,000. Kestra Private Wealth Services LLC acquired a new position in shares of Grace Therapeutics in the 1st quarter valued at approximately $60,000. SeaCrest Wealth Management LLC bought a new stake in shares of Grace Therapeutics during the 3rd quarter worth approximately $42,000. XTX Topco Ltd bought a new stake in shares of Grace Therapeutics during the 4th quarter worth approximately $106,000. Finally, Pale Fire Capital SE bought a new stake in shares of Grace Therapeutics during the 1st quarter worth approximately $175,000. Institutional investors own 6.08% of the company’s stock.

Grace Therapeutics Trading Down 1.3%

Shares of NASDAQ GRCE opened at $2.30 on Tuesday. The company has a market cap of $37.43 million, a price-to-earnings ratio of -4.79 and a beta of 0.37. Grace Therapeutics, Inc. has a 12 month low of $1.79 and a 12 month high of $5.18. The stock has a 50-day moving average price of $2.36 and a two-hundred day moving average price of $3.23.

Grace Therapeutics (NASDAQ:GRCE) last posted its quarterly earnings results on Thursday, June 18th. The company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.17. On average, sell-side analysts predict that Grace Therapeutics, Inc. will post -0.8 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Grace Therapeutics in a research note on Friday, July 17th. Wall Street Zen upgraded Grace Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, June 27th. Craig Hallum set a $4.00 target price on Grace Therapeutics in a report on Friday, April 24th. Finally, TD Cowen decreased their price target on Grace Therapeutics from $12.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, April 24th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $6.00.

About Grace Therapeutics

Grace Therapeutics, Inc (NASDAQ: GRCE) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for rare genetic diseases. By employing a proprietary platform that integrates advanced molecular biology and biologic engineering, the company focuses on identifying and optimizing gene-based and protein-based candidates designed to address well-defined genetic drivers of disease.

The company’s pipeline features multiple preclinical programs targeting lysosomal storage disorders and other inherited metabolic conditions.